Perioperative Care of Patients with Neuromuscular Disease and Dysfunction

Anesthesiology Clinics

Volumn 25, Issue 3, 2007, Pages 483-509

  Brambrink, Ansgar M ^a   Kirsch, Jeffrey R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; ANESTHETIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DANTROLENE; GLYCERYL TRINITRATE; IMMUNOGLOBULIN; INTERFERON; LOCAL ANESTHETIC AGENT; METHYLPREDNISOLONE; NEOSTIGMINE; NIFEDIPINE; PROPOFOL; PYRIDOSTIGMINE; RILUZOLE; SUXAMETHONIUM; THIOPENTAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANESTHESIA; CRITICAL ILLNESS POLYNEUROPATHY; DUCHENNE MUSCULAR DYSTROPHY; EATON LAMBERT SYNDROME; FRIEDREICH ATAXIA; GUILLAIN BARRE SYNDROME; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HYPERKALEMIA; LOW DRUG DOSE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NERVE CELL DEGENERATION; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PEROPERATIVE CARE; PHYSIOTHERAPY; PLASMAPHERESIS; POLYNEUROPATHY; REVIEW; SPASTICITY; SPINAL CORD INJURY; SPINAL MUSCULAR ATROPHY;

ANESTHESIA, GENERAL; ANESTHESIOLOGY; ANESTHETICS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR DISEASES; PERIOPERATIVE CARE;

EID: 34548607930     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2007.05.005     Document Type: Review

References (235)

1. D'Angelo M.G., and Bresolin N. Cognitive impairment in neuromuscular disorders. Muscle Nerve 34 1 (2006) 16-33
2. Girshin M., Mukherjee J., Clowney R., et al. The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne's muscular dystrophy. Paediatr Anaesth 16 2 (2006) 170-173
3. Gronert G.A. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 94 3 (2001) 523-529
4. Larach M.G., Rosenberg H., Gronert G.A., et al. Did anesthetics trigger cardiac arrests in patients with occult myopathies?. Anesthesiology 94 5 (2001) 933-935
5. Mathieu J., Allard P., Gobeil G., et al. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 49 6 (1997) 1646-1650
6. Klinge L., Eagle M., Haggerty I.D., et al. Severe phenotype in infantile facioscapulohumeral muscular dystrophy. Neuromuscul Disord 16 9-10 (2006) 553-558
7. Bushby K.M., Hill A., and Steele J.G. Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet 353 9152 (1999) 557-558
8. Zanette G., Robb N., Zadra N., et al. Undetected central core disease myopathy in an infant presenting for clubfoot surgery. Paediatr Anaesth 17 4 (2007) 380-382
9. Zanette G., Manani G., Pittoni G., et al. Prevalence of unsuspected myopathy in infants presenting for clubfoot surgery. Paediatr Anaesth 5 3 (1995) 165-170
10. Kernstine K.H. Preoperative preparation of the patient with myasthenia gravis. Thorac Surg Clin 15 2 (2005) 287-295
11. Franklin J.A., Lalikos J.F., and Wooden W.A. A case of mitochondrial myopathy and cleft palate. Cleft Palate Craniofac J 42 3 (2005) 327-330
12. Rowland L.P., and Shneider N.A. Amyotrophic lateral sclerosis. N Engl J Med 344 22 (2001) 1688-1700
13. Pasinetti G.M., Ungar L.H., Lange D.J., et al. Identification of potential CSF biomarkers in ALS. Neurology 66 8 (2006) 1218-1222
14. Monani U.R. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron 48 6 (2005) 885-896
15. Moser B., Lirk P., Lechner M., et al. General anaesthesia in a patient with motor neuron disease. Eur J Anaesthesiol 21 11 (2004) 921-923
16. Otsuka N., Igarashi M., Shimodate Y., et al. [Anesthetic management of two patients with amyotrophic lateral sclerosis (ALS)]. Masui 53 11 (2004) 1279-1281 [in Japanese]
17. Veen A., Molenbuur B., and Richardson F.J. Epidural anaesthesia in a child with possible spinal muscular atrophy. Paediatr Anaesth 12 6 (2002) 556-558
18. Fiacchino F., Gemma M., Bricchi M., et al. Sensitivity to curare in patients with upper and lower motor neurone dysfunction. Anaesthesia 46 11 (1991) 980-982
19. Kuisma M.J., Saarinen K.V., and Teirmaa H.T. Undiagnosed amyotrophic lateral sclerosis and respiratory failure. Acta Anaesthesiol Scand 37 6 (1993) 628-630
20. Leypold B.G., Flanders A.E., Schwartz E.D., et al. The impact of methylprednisolone on lesion severity following spinal cord injury. Spine 32 3 (2007) 373-378
21. Dutton R.P. Anesthetic management of spinal cord injury: clinical practice and future initiatives. Int Anesthesiol Clin 40 3 (2002) 103-120
22. Crosby E.T. Airway management in adults after cervical spine trauma. Anesthesiology 104 6 (2006) 1293-1318
23. Bracken M.B., Shepard M.J., Collins W.F., et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322 20 (1990) 1405-1411
24. Bracken M.B. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 3 (2002) CD001046
25. Qian T., Campagnolo D., and Kirshblum S. High-dose methylprednisolone may do more harm for spinal cord injury. Med Hypotheses 55 5 (2000) 452-453
26. Tator C.H. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 59 5 (2006) 957-982
27. Tsutsumi S., Ueta T., Shiba K., et al. Effects of the Second National Acute Spinal Cord Injury Study of high-dose methylprednisolone therapy on acute cervical spinal cord injury-results in spinal injuries center. Spine 31 26 (2006) 2992-2996
28. Sipski M.L., and Pearse D.D. Methylprednisolone and other confounders to spinal cord injury clinical trials. Nat Clin Pract Neurol 2 8 (2006) 402-403
29. Martyn J.A., White D.A., Gronert G.A., et al. Up-and-down regulation of skeletal muscle acetylcholine receptors: effects on neuromuscular blockers. Anesthesiology 76 5 (1992) 822-843
30. Stone W.A., Beach T.P., and Hamelberg W. Succinylcholine-danger in the spinal-cord-injured patient. Anesthesiology 32 2 (1970) 168-169
31. Tobey R.E. Paraplegia, succinylcholine and cardiac arrest. Anesthesiology 32 4 (1970) 359-364
32. John D.A., Tobey R.E., Homer L.D., et al. Onset of succinylcholine-induced hyperkalemia following denervation. Anesthesiology 45 3 (1976) 294-299
33. Gronert G.A. Use of suxamethonium in cord patients: whether and when. Anaesthesia 53 10 (1998) 1035-1036
34. Pope C.S., Markenson G.R., Bayer-Zwirello L.A., et al. Pregnancy complicated by chronic spinal cord injury and history of autonomic hyperreflexia. Obstet Gynecol 97 5 Pt 2 (2001) 802-803
35. Burns R., and Clark V.A. Epidural anaesthesia for caesarean section in a patient with quadriplegia and autonomic hyperreflexia. Int J Obstet Anesth 13 2 (2004) 120-123
36. Pereira L. Obstetric management of the patient with spinal cord injury. Obstet Gynecol Surv 58 10 (2003) 678-687
37. Khan A., Haque S., and Hyder Z. Outcome from percutaneous nephrolithotomy in patients with spinal cord injury, using a single-stage dilator for access. BJU Int 96 9 (2005) 1423
38. Cosman B.C., and Vu T.T. Lidocaine anal block limits autonomic dysreflexia during anorectal procedures in spinal cord injury: a randomized, double-blind, placebo-controlled trial. Dis Colon Rectum 48 8 (2005) 1556-1561
39. Kantarci O., and Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 19 3 (2006) 248-254
40. Langer-Gould A., Popat R.A., Huang S.M., et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 63 12 (2006) 1686-1691
41. Fog M., and Hyllested K. Prevalence of disseminated sclerosis in the Faroes, the Orkneys and Shetland. Acta Neurol Scand 42 Suppl 19 (1966) 9-11
42. Wasay M., Khatri I.A., Khealani B., et al. MS in Asian countries. Int MS J 13 2 (2006) 58-65
43. Marrie R.A. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3 12 (2004) 709-718
44. Sadovnick A.D., Dyment D., and Ebers G.C. Genetic epidemiology of multiple sclerosis. Epidemiol Rev 19 1 (1997) 99-106
45. Imitola J., Chitnis T., and Khoury S.J. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 63 1 (2006) 25-33
46. Fawcett J.W., and Asher R.A. The glial scar and central nervous system repair. Brain Res Bull 49 6 (1999) 377-391
47. Correale J., and de los Milagros Bassani Molinas M. Oligoclonal bands and antibody responses in multiple sclerosis. J Neurol 249 4 (2002) 375-389
48. Calza L., Fernandez M., Giuliani A., et al. Thyroid hormone and remyelination in adult central nervous system: a lesson from an inflammatory-demyelinating disease. Brain Res Brain Res Rev 48 2 (2005) 339-346 [Epub 2005 Jan 26]
49. Vedula S.S., Brodney-Folse S., Gal R.L., et al. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 1 (2007) CD001430
50. Pirko I., Lucchinetti C.F., Sriram S., et al. Gray matter involvement in multiple sclerosis. Neurology 68 9 (2007) 634-642
51. Pierson S.H., and Griffith N. Treatment of cognitive impairment in multiple sclerosis. Behav Neurol 17 1 (2006) 53-67
52. Ameis S.H., and Feinstein A. Treatment of neuropsychiatric conditions associated with multiple sclerosis. Expert Rev Neurother 6 10 (2006 Oct) 1555-1567
53. Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci 245 1-2 (2006) 63-66 [Epub 2006 Apr 27]
54. Rickards H. Depression in neurological disorders: an update. Curr Opin Psychiatry 19 3 (2006) 294-298
55. Navarro S., Mondejar-Marin B., Pedrosa-Guerrero A., et al. Aphasia and parietal syndrome as the presenting symptoms of a demyelinating disease with pseudotumoral lesions. Rev Neurol 41 10 (2005) 601-603
56. Jongen P.J. Psychiatric onset of multiple sclerosis. J Neurol Sci 245 1-2 (2006) 59-62
57. Rees P.M., Fowler C.J., and Maas C.P. Sexual function in men and women with neurological disorders. Lancet 369 9560 (2007) 512-525
58. Poser C.M., and Brinar V.V. Epilepsy and multiple sclerosis. Epilepsy Behav 4 1 (2003) 6-12
59. Kleinschnitz C., Meuth S.G., Kieseier B.C., et al. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 7 1 (2007) 35-63
60. Taylor N.F., Dodd K.J., Shields N., et al. Therapeutic exercise in physiotherapy practice is beneficial: a summary of systematic reviews 2002-2005. Aust J Physiother 53 1 (2007) 7-16
61. De Jager P.L., and Hafler D.A. New therapeutic approaches for multiple sclerosis. Annu Rev Med 58 (2007) 417-432
62. Dorotta I.R., and Schubert A. Multiple sclerosis and anesthetic implications. Curr Opin Anaesthesiol 15 3 (2002) 365-370
63. Schneider K.M. AANA Journal course: update for nurse anesthetists-an overview of multiple sclerosis and implications for anesthesia. [review]. AANA J 73 3 (2005) 217-224
64. Ferrero S., Pretta S., and Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 115 1 (2004) 3-9
65. Smeltzer S.C., Skurnick J.H., Troiano R., et al. Respiratory function in multiple sclerosis: utility of clinical assessment of respiratory muscle function. Chest 101 2 (1992) 479-484
66. Rabadan Diaz J.V., Lopez Moreno J.A., Soria Quiles A., et al. Neurological deficit during recovery from cesarean section under spinal anesthesia after the appearance of undiagnosed multiple sclerosis. Rev Esp Anestesiol Reanim 53 10 (2006) 673-674
67. Perlas A., and Chan V.W. Neuraxial anesthesia and multiple sclerosis. Can J Anaesth 52 5 (2005) 454-458
68. Finucane B.T., and Terblanche O.C. Prolonged duration of anesthesia in a patient with multiple sclerosis following paravertebral block. Can J Anaesth 52 5 (2005) 493-497
69. Marshak D.S., Neustein S.M., and Thomson J. The use of thoracic epidural analgesia in a patient with multiple sclerosis and severe kyphoscoliosis. J Cardiothorac Vasc Anesth 20 5 (2006) 704-706 [Epub 2006 May 30]
70. Drake E., Drake M., Bird J., et al. Obstetric regional blocks for women with multiple sclerosis: a survey of UK experience. Int J Obstet Anesth 15 2 (2006) 115-123 [Epub 2006 Feb 20]
71. Ingrosso M., Cirillo V., Papasso A., et al. Femoral and sciatic nerves block (BiBlock) in orthopedic traumatologic lower limbs surgery in patients with multiple sclerosis. Minerva Anestesiol 71 5 (2005) 223-226
72. Cooperman L.H. Succinylcholine-induced hyperkalemia in neuromuscular disease. JAMA 213 11 (1970) 1867-1871
73. Brett R.S., Schmidt J.H., Gage J.S., et al. Measurement of acetylcholine receptor concentration in skeletal muscle from a patient with multiple sclerosis and resistance to atracurium. Anesthesiology 66 6 (1987) 837-839
74. Kim C.S., Arnold F.J., Itani M.S., et al. Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes. Anesthesiology 77 3 (1992) 500-506
75. Couch J.R., and Hassanein R.S. Platelet hyperaggregability in multiple sclerosis. Trans Am Neurol Assoc 102 (1977) 62-64
76. Feuillet L., Guedj E., Laksiri N., et al. Deep vein thrombosis after intravenous immunoglobulins associated with methylprednisolone. Thromb Haemost 92 3 (2004) 662-665
77. Krajewski K.M., Lewis R.A., Fuerst D.R., et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 123 Pt 7 (2000) 1516-1527
78. Baloh R.H., Schmidt R.E., Pestronk A., et al. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 27 2 (2007) 422-430
79. Delatycki M.B., Holian A., Corben L., et al. Surgery for equinovarus deformity in Friedreich's ataxia improves mobility and independence. Clin Orthop Relat Res 430 (2005) 138-141
80. Schapira A.H. Mitochondrial disease. Lancet 368 9529 (2006) 70-82
81. Rudnik-Schoneborn S., Rohrig D., Nicholson G., et al. Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 43 10 (1993) 2011-2016
82. Antognini J.F. Anaesthesia for Charcot-Marie-Tooth disease: a review of 86 cases. Can J Anaesth 39 4 (1992) 398-400
83. Kotani N., Hirota K., Anzawa N., et al. Motor and sensory disability has a strong relationship to induction dose of thiopental in patients with the hypertropic variety of Charcot-Marie-Tooth syndrome. Anesth Analg 82 1 (1996) 182-186
84. Schmitt H.J., Muenster T., and Schmidt J. Central neural blockade in Charcot-Marie-Tooth disease. Can J Anaesth 51 10 (2004) 1049-1050
85. Schmitt H.J., Wick S., and Munster T. Onset and duration of mivacurium-induced neuromuscular blockade in children with Charcot-Marie-Tooth disease: a case series with five children. Paediatr Anaesth 16 2 (2006) 182-187
86. He X., Sullivan E.V., Stankovic R.K., et al. Interaction of thiamine deficiency and voluntary alcohol consumption disrupts rat corpus callosum ultrastructure. Neuropsychopharmacology (2007) [Epub ahead of print]
87. Okamoto H., Miki T., Lee K.Y., et al. Oligodendrocyte myelin glycoprotein (OMgp) in rat hippocampus is depleted by chronic ethanol consumption. Neurosci Lett 406 1-2 (2006) 76-80
88. Kuwabara S. Guillain-Barré syndrome. Curr Neurol Neurosci Rep 7 1 (2007) 57-62
89. Douglas M.R., and Winer J.B. Guillain-Barre syndrome and its treatment. Expert Rev Neurother 6 10 (2006) 1569-1574
90. Steiner I., Argov Z., Cahan C., et al. Guillain-Barre syndrome after epidural anesthesia: direct nerve root damage may trigger disease. Neurology 35 10 (1985) 1473-1475
91. Wiertlewski S., Magot A., Drapier S., et al. Worsening of neurologic symptoms after epidural anesthesia for labor in a Guillain-Barre patient. Anesth Analg 98 3 (2004) 825-827
92. Otermin Maya I., Pereda Garcia A., Lopez Aldaz M., et al. Post-anesthesia recurrence of Guillain-Barre syndrome. Med Clin (Barc) 127 3 (2006) 118-119
93. Flores-Barragan J.M., Martinez-Palomeque G., Ibanez R., et al. Guillain-Barre syndrome as a complication of epidural anaesthesia. Rev Neurol 42 10 (2006) 631-632
94. Lehmann H.C., Hartung H.P., Hetzel G.R., et al. Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63 7 (2006) 930-935
95. Lehmann H.C., Hartung H.P., Hetzel G.R., et al. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 63 8 (2006) 1066-1071
96. Koski C.L., and Patterson J.V. Intravenous immunoglobulin use for neurologic diseases. J Infus Nurs 29 3 Suppl (2006) S21-S28
97. Chan L.Y., Tsui M.H., and Leung T.N. Guillain-Barre syndrome in pregnancy. Acta Obstet Gynecol Scand 83 4 (2004) 319-325
98. Brooks H., Christian A.S., and May A.E. Pregnancy, anaesthesia and Guillain Barre syndrome. Anaesthesia 55 9 (2000) 894-898
99. Dalman J.E., and Verhagen W.I. Cardiac arrest in Guillain-Barre syndrome and the use of suxamethonium. Acta Neurol Belg 94 4 (1994) 259-261
100. Reilly M., and Hutchinson M. Suxamethonium is contraindicated in the Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 54 11 (1991) 1018-1019
101. Feldman J.M. Cardiac arrest after succinylcholine administration in a pregnant patient recovered from Guillain-Barre syndrome. Anesthesiology 72 5 (1990) 942-944
102. Dhand U.K. Clinical approach to the weak patient in the intensive care unit. Respir Care 51 9 (2006) 1024-1040
103. Fiacchino F., Gemma M., Bricchi M., et al. Hypo- and hypersensitivity to vecuronium in a patient with Guillain-Barre syndrome. Anesth Analg 78 1 (1994) 187-189
104. Visser L.H. Critical illness polyneuropathy and myopathy: clinical features, risk factors and prognosis. Eur J Neurol 13 11 (2006) 1203-1212
105. Hund E. Critical illness polyneuropathy. Curr Opin Neurol 14 5 (2001) 649-653
106. Leijten F.S., and de Weerd A.W. Critical illness polyneuropathy, facts and controversies. J Peripher Nerv Syst 1 1 (1996) 28-33
107. Leijten F.S., and de Weerd A.W. Critical illness polyneuropathy: a review of the literature, definition and pathophysiology. Clin Neurol Neurosurg 96 1 (1994) 10-19
108. Williams S., Horrocks I.A., Ouvrier R.A., et al. Critical illness polyneuropathy and myopathy in pediatric intensive care: a review. Pediatr Crit Care Med 8 1 (2007) 18-22
109. Banwell B.L., Mildner R.J., Hassall A.C., et al. Muscle weakness in critically ill children. Neurology 61 12 (2003) 1779-1782
110. Leijten F.S., De Weerd A.W., Poortvliet D.C., et al. Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 22 9 (1996) 856-861
111. Witt N.J., Zochodne D.W., Bolton C.F., et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 99 1 (1991) 176-184
112. Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 248 11 (2001) 929-934
113. Hough C.L. Neuromuscular sequelae in survivors of acute lung injury. Clin Chest Med 27 4 (2006) 691-703
114. Hund E., Genzwurker H., Bohrer H., et al. Predominant involvement of motor fibres in patients with critical illness polyneuropathy. Br J Anaesth 78 3 (1997) 274-278
115. Nates J.L., Cooper D.J., Day B., et al. Acute weakness syndromes in critically ill patients: a reappraisal. Anaesth Intensive Care 25 5 (1997) 502-513
116. Biccard B.M., Grant I.S., Wright D.J., et al. Suxamethonium and critical illness polyneuropathy. Anaesth Intensive Care 26 5 (1998) 590-591
117. Geller T.J., Kaiboriboon K., Fenton G.A., et al. Vecuronium-associated axonal motor neuropathy: a variant of critical illness polyneuropathy?. Neuromuscul Disord 11 6-7 (2001) 579-582
118. Hara K., Minami K., Takamoto K., et al. The prolonged effect of a muscle relaxant in a patient with chronic inflammatory demyelinating polyradiculoneuropathy. Anesth Analg 90 1 (2000) 224-226
119. Tuxen D.V., Day B.J., and Scheinkestel C.D. Acute respiratory failure neuropathy: a variant of critical illness polyneuropathy. Crit Care Med 21 12 (1993) 1986-1987
120. Engel A.G. The therapy of congenital myasthenic syndromes. Neurotherapeutics 4 2 (2007) 252-257
121. Wittbrodt E.T. Drugs and myasthenia gravis: an update. Arch Intern Med 157 4 (1997) 399-408
122. Rajasekaran D., Chandrasekar S., and Rajendran M. Drug related crisis in myasthenia gravis. J Assoc Physicians India 54 (2006) 820-821 [erratum in: J Assoc Physicians India. 2006 Nov;54:889]
123. Feldman S., and Karalliedde L. Drug interactions with neuromuscular blockers. Drug Saf 15 4 (1996) 261-273
124. Ferrero S., Pretta S., Nicoletti A., et al. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 121 2 (2005) 129-138
125. Scherer K., Bedlack R.S., and Simel D.L. Does this patient have myasthenia gravis?. JAMA 293 (2005) 1906-1914
126. Phillips L.H. The epidemiology of myasthenia gravis. Semin Neurol 24 1 (2004) 17-20
127. Evoli A. Clinical aspects of neuromuscular transmission disorders. Acta Neurol Scand Suppl 183 (2006) 8-11
128. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 116 11 (2006) 2843-2854
129. Vincent A. Immunology of disorders of neuromuscular transmission. Acta Neurol Scand Suppl 183 (2006) 1-7
130. Vincent A., and Leite M.I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18 5 (2005) 519-525
131. Osserman K.E., and Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38 (1971) 497-537
132. Vincent A., and Rothwell P. Myasthenia gravis. Autoimmunity 37 4 (2004) 317-319
133. Lindstrom J.M. Acetylcholine receptors and myasthenia. Muscle Nerve 23 4 (2000) 453-477
134. Sieb J.P. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 5 3 (2005) 303-307
135. Gronseth G.S., and Barohn R.J. Thymectomy for myasthenia gravis. Curr Treat Options Neurol 4 3 (2002) 203-209
136. White M.C., and Stoddart P.A. Anesthesia for thymectomy in children with myasthenia gravis. Paediatr Anaesth 14 8 (2004) 625-635
137. Dillon F.X. Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 24 1 (2004) 83-94
138. Mygland A., Aarli J.A., Hofstad H., et al. Heart muscle antibodies in myasthenia gravis. Autoimmunity 10 4 (1991) 263-267
139. de Jongste M.J., Oosterhuis H.J., and Lie K.I. Intractable ventricular tachycardia in a patient with giant cell myocarditis, thymoma and myasthenia gravis. Int J Cardiol 13 3 (1986) 374-378
140. Lin T.C., Hsu C.H., Kong S.S., et al. Ventricular asystole and complete heart block after thoracic epidural analgesia for thymectomy. Eur J Anaesthesiol 19 6 (2002) 460-462
141. Inoue S., Shiomi T., and Furuya H. Severe bradycardia in a patient with myasthenia gravis during transurethral ureterolithotripsic procedure under spinal anaesthesia. Anaesth Intensive Care 30 3 (2002) 387
142. Abel M., and Eisenkraft J.B. Anesthetic implications of myasthenia gravis. Mt Sinai J Med 69 1-2 (2002) 31-37
143. Barrons R.W. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy 17 6 (1997) 1220-1232
144. de Jose Maria B., Carrero E., and Sala X. Myasthenia gravis and regional anaesthesia. Can J Anaesth 42 2 (1995) 178-179
145. Mekis D., and Kamenik M. Remifentanil and high thoracic epidural anaesthesia: a successful combination for patients with myasthenia gravis undergoing transsternal thymectomy. Eur J Anaesthesiol 22 5 (2005) 397-9
146. Levitan R. Safety of succinylcholine in myasthenia gravis. Ann Emerg Med 45 2 (2005) 225-226
147. Kadoi Y., Hinohara H., Kunimoto F., et al. Is the degree of sensitivity to nondepolarizing muscle relaxants related to requirements for postoperative ventilation in patients with myasthenia gravis?. Anaesth Intensive Care 32 3 (2004) 346-350
148. De Haes A., Proost J.H., De Baets M.H., et al. Decreased number of acetylcholine receptors is the mechanism that alters the time course of muscle relaxants in myasthenia gravis: a study in a rat model. Eur J Anaesthesiol 22 8 (2005) 591-596
149. de Lemos J.M., Carr R.R., Shalansky K.F., et al. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion. Crit Care Med 27 12 (1999) 2648-2655
150. De Haes A., Proost J.H., Kuks J.B., et al. Pharmacokinetic/pharmacodynamic modeling of rocuronium in myasthenic patients is improved by taking into account the number of unbound acetylcholine receptors. Anesth Analg 95 3 (2002) 588-596 table of contents
151. Tripathi M., Kaushik S., and Dubey P. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis. J Postgrad Med 49 4 (2003) 311-314 [discussion: 314-15]
152. Itoh H., Shibata K., and Nitta S. Sensitivity to vecuronium in seropositive and seronegative patients with myasthenia gravis. Anesth Analg 95 1 (2002) 109-113
153. Mann R., Blobner M., Jelen-Esselborn S., et al. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients. Anesthesiology 93 2 (2000) 346-350
154. Kirsch J.R., Diringer M.N., Borel C.O., et al. Preoperative lumbar epidural morphine improves postoperative analgesia and ventilatory function after transsternal thymectomy in patients with myasthenia gravis. Crit Care Med 19 12 (1991) 1474-1479
155. Mareska M., and Gutmann L. Lambert-Eaton myasthenic syndrome. Semin Neurol 24 2 (2004) 149-153
156. Wirtz P.W., Bradshaw J., Wintzen A.R., et al. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 251 10 (2004) 1255-1259
157. Sidnev D.V., Karganov M.Y., Shcherbakova N.I., et al. Antibodies to acetylcholine receptors in patients with different clinical forms of myasthenia and Lambert-Eaton myasthenic syndrome. Neurosci Behav Physiol 37 2 (2007) 129-131
158. O'Neill G.N. Acquired disorders of the neuromuscular junction. Int Anesthesiol Clin 44 2 (2006) 107-121
159. Verschuuren J.J., Wirtz P.W., Titulaer M.J., et al. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 7 10 (2006) 1323-1336
160. Maddison P., and Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2 (2005) CD003279
161. Small S., Ali H.H., Lennon V.A., et al. Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. Anesthesiology 76 1 (1992) 142-145
162. Telford R.J., and Hollway T.E. The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine. Br J Anaesth 64 3 (1990) 363-366
163. Trip J., Drost G., van Engelen B.G., et al. Drug treatment for myotonia. Cochrane Database Syst Rev 1 (2006) CD004762
164. Huang C.C., and Kuo H.C. Myotonic dystrophies. Chang Gung Med J 28 8 (2005) 517-526
165. White R.J., and Bass S.P. Myotonic dystrophy and paediatric anaesthesia. Paediatr Anaesth 13 2 (2003) 94-102
166. Novakovic I., Bojic D., Todorovic S., et al. Proximal dystrophin gene deletions and protein alterations in Becker muscular dystrophy. Ann N Y Acad Sci 1048 (2005) 406-410
167. Drouet A., Leturcq F., Guilloton L., et al. Muscular exercise intolerance syndrome in Becker muscular dystrophy. Presse Med 31 5 (2002) 197-201
168. Muchir A., and Worman H.J. Emery-Dreifuss muscular dystrophy. Curr Neurol Neurosci Rep 7 1 (2007) 78-83
169. Ifergane G., Al-Sayed I., Birk O., et al. Co-morbidity of Emery-Dreifuss muscular dystrophy and a congenital myasthenic syndrome possibly affecting the phenotype in a large Bedouin kindred. Eur J Neurol 14 3 (2007) 305-308
170. English K.M., and Gibbs J.L. Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders. Dev Med Child Neurol 48 3 (2006) 231-235
171. Choudhry D.K., and Mackenzie W.G. Anesthetic issues with a hyperextended cervical spine in a child with Emery-Dreifuss syndrome. Anesth Analg 103 6 (2006) 1611-1613
172. Shende D., and Agarwal R. Anaesthetic management of a patient with Emery-Dreifuss muscular dystrophy. Anaesth Intensive Care 30 3 (2002) 372-375
173. Callen J.P., and Wortmann R.L. Dermatomyositis. Clin Dermatol 24 5 (2006) 363-373
174. Rockelein S., Gebert M., Baar H., et al. Neuromuscular blockade with atracurium in dermatomyositis. Anaesthesist 44 6 (1995) 442-444
175. Ganta R., Campbell I.T., and Mostafa S.M. Anaesthesia and acute dermatomyositis/polymyositis. Br J Anaesth 60 7 (1988) 854-858
176. Quain R.D., and Werth V.P. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol 7 6 (2006) 341-351
177. Briani C., Doria A., Sarzi-Puttini P., et al. Update on idiopathic inflammatory myopathies. Autoimmunity 39 3 (2006) 161-170
178. Saarnivaara L.H. Anesthesia for a patient with polymyositis undergoing myectomy of the cricopharyngeal muscle. Anesth Analg 67 7 (1988) 701-702
179. Sasano N., Fujita Y., So M., et al. Anesthetic management of a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) during laparotomy. J Anesth 21 1 (2007) 72-75
180. Allison K.R. Muscular dystrophy versus mitochondrial myopathy: the dilemma of the undiagnosed hypotonic child. Paediatr Anaesth 17 1 (2007) 1-6
181. Shipton E.A., and Prosser D.O. Mitochondrial myopathies and anaesthesia. Eur J Anaesthesiol 21 3 (2004) 173-178
182. Driessen J., Willems S., Dercksen S., et al. Anesthesia-related morbidity and mortality after surgery for muscle biopsy in children with mitochondrial defects. Paediatr Anaesth 17 1 (2007) 16-21
183. Mastaglia F.L. Neuromuscular disorders: molecular and therapeutic insights. Lancet Neurol 4 1 (2005) 6-7
184. Nakajima H., Raben N., Hamaguchi T., et al. Phosphofructokinase deficiency; past, present and future. Curr Mol Med 2 2 (2002) 197-212
185. Servidei S., and DiMauro S. Disorders of glycogen metabolism of muscle. Neurol Clin 7 1 (1989) 159-178
186. Ing R.J., Cook D.R., Bengur R.A., et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth 14 6 (2004) 514-519
187. Klingler W., Lehmann-Horn F., and Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 15 3 (2005) 195-206 [Epub 2005 Jan 28]
188. Darras B.T., and Friedman N.R. Metabolic myopathies: a clinical approach; part II. Pediatr Neurol 22 3 (2000) 171-181
189. Cwik V.A. Disorders of lipid metabolism in skeletal muscle. Neurol Clin 18 1 (2000) 167-184
190. Wallgren-Pettersson C., and Laing N.G. 109th ENMC International Workshop: 5th workshop on nemaline myopathy, 11th-13th October 2002, Naarden, The Netherlands. Neuromuscul Disord 13 6 (2003) 501-507
191. Udd B., Meola G., Krahe R., et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 16 6 (2006) 403-413
192. Wallgren-Pettersson C. Nemaline and myotubular myopathies. Semin Pediatr Neurol 9 2 (2002) 132-144
193. Ryan M.M., Schnell C., Strickland C.D., et al. Nemaline myopathy: a clinical study of 143 cases. Ann Neurol 50 3 (2001) 312-320
194. Stackhouse R., Chelmow D., and Dattel B.J. Anesthetic complications in a pregnant patient with nemaline myopathy. Anesth Analg 79 6 (1994) 1195-1197
195. Shenkman Z., Sheffer O., Erez I., et al. Spinal anesthesia for gastrostomy in an infant with nemaline myopathy. Anesth Analg 91 4 (2000) 858-859
196. Talwalkar S.S., Parker J.R., Heffner R.R., et al. Adult central core disease. Clinical, histologic and genetic aspects: case report and review of the literature. Clin Neuropathol 25 4 (2006) 180-184
197. Priori S.G., and Napolitano C. Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. J Clin Invest 115 8 (2005) 2033-2038
198. Avila G. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved. Cell Calcium 37 2 (2005) 121-127
199. McCarthy T.V., Quane K.A., and Lynch P.J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 15 5 (2000) 410-417
200. Townsend D., Yasuda S., and Metzger J. Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach. Expert Rev Cardiovasc Ther 5 1 (2007) 99-109
201. Simonds A.K. Recent advances in respiratory care for neuromuscular disease. Chest 130 6 (2006) 1879-1886
202. Finsterer J. Cardiopulmonary support in Duchenne muscular dystrophy. Lung 184 4 (2006) 205-215
203. Deconinck N., and Dan B. Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 36 1 (2007) 1-7
204. Anderson J.E., Hansen L.L., Mooren F.C., et al. Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicine. Drug Resist Updat 9 4-5 (2006) 198-210
205. Allard B. Sarcolemmal ion channels in dystrophin-deficient skeletal muscle fibres. J Muscle Res Cell Motil 27 5-7 (2006) 367-373
206. Gissel H. The role of Ca2+ in muscle cell damage. Ann N Y Acad Sci 1066 (2005) 166-180
207. Naguib M., Flood P., McArdle J.J., et al. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 96 1 (2002) 202-231
208. Sekiguchi M. The role of dystrophin in the central nervous system: a mini review. Acta Myol 24 2 (2005) 93-97
209. Wagner K.R., Lechtzin N., and Judge D.P. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 1772 2 (2007) 229-237
210. Patel K., Macharia R., and Amthor H. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. Acta Myol 24 3 (2005) 230-241
211. Ames W.A., Hayes J.A., and Crawford M.W. The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist. Paediatr Anaesth 15 1 (2005) 3-8
212. Blake D.J., and Kroger S. The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle?. Trends Neurosci 23 3 (2000) 92-99
213. Allen G.C. Malignant hyperthermia and associated disorders. Curr Opin Rheumatol 5 6 (1993) 719-724
214. Ali S.Z., Taguchi A., and Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 17 4 (2003) 519-533
215. Smelt W.L. Cardiac arrest during desflurane anaesthesia in a patient with Duchenne's muscular dystrophy. Acta Anaesthesiol Scand 49 2 (2005) 267-269
216. Nathan A., Ganesh A., Godinez R.I., et al. Hyperkalemic cardiac arrest after cardiopulmonary bypass in a child with unsuspected Duchenne muscular dystrophy. Anesth Analg 100 3 (2005) 672-674
217. Tokunaga C., Hiramatsu Y., Noma M., et al. Delayed onset malignant hyperthermia after a closure of ventricular septal defect. Kyobu Geka 58 3 (2005) 201-205
218. Hayes J.A., and Ames W.A. Acute heart failure during spinal surgery in a boy with Duchenne muscular dystrophy. Br J Anaesth 92 1 (2004) 149
219. Takagi A. [Malignant hyperthermia of Duchenne muscular dystrophy: application of clinical grading scale and caffeine contracture of skinned muscle fibers]. Rinsho Shinkeigaku 40 5 (2000) 423-427 [in Japanese]
220. Breucking E., Reimnitz P., Schara U., et al. Anesthetic complications: the incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types. Anaesthesist 49 3 (2000) 187-195
221. Hu J., Higuchi I., Inose M., et al. Characteristic expression of thrombomodulin in the muscle sarcoplasm in patients with the acute phase of rhabdomyolysis. Eur Neurol 43 3 (2000) 174-180
222. Takahashi H., Shimokawa M., Sha K., et al. Sevoflurane can induce rhabdomyolysis in Duchenne's muscular dystrophy. Masui 51 2 (2002) 190-192
223. Flick R.P., Gleich S.J., Herr M.M., et al. The risk of malignant hyperthermia in children undergoing muscle biopsy for suspected neuromuscular disorder. Paediatr Anaesth 17 1 (2007) 22-27
224. Pruijs J.E., van Tol M.J., van Kesteren R.G., et al. Neuromuscular scoliosis: clinical evaluation pre- and postoperative. J Pediatr Orthop B 9 4 (2000) 217-220
225. Harper C.M., Ambler G., and Edge G. The prognostic value of pre-operative predicted forced vital capacity in corrective spinal surgery for Duchenne's muscular dystrophy. Anaesthesia 59 12 (2004) 1160-1162
226. Almenrader N., and Patel D. Spinal fusion surgery in children with non-idiopathic scoliosis: is there a need for routine postoperative ventilation?. Br J Anaesth 97 6 (2006) 851-857
227. Yemen T.A., and McClain C. Muscular dystrophy, anesthesia and the safety of inhalational agents revisited, again. Paediatr Anaesth 16 2 (2006) 105-108
228. Schmitt H.J., Schmidt J., and Muenster T. Dystrophin deficiency, inhalational anesthetics, and rhabdomyolysis. Paediatr Anaesth 17 1 (2007) 94-95
229. Kawaai H., Tanaka K., and Yamazaki S. Continuous infusion propofol general anesthesia for dental treatment in patients with progressive muscular dystrophy. Anesth Prog 52 1 (2005) 12-16
230. Molyneux M.K. Anaesthetic management during labour of a manifesting carrier of Duchenne muscular dystrophy. Int J Obstet Anesth 14 1 (2005) 58-61
231. Schmidt J., Muenster T., Wick S., et al. Onset and duration of mivacurium-induced neuromuscular block in patients with Duchenne muscular dystrophy. Br J Anaesth 95 6 (2005) 769-772
232. Wick S., Muenster T., Schmidt J., et al. Onset and duration of rocuronium-induced neuromuscular blockade in patients with Duchenne muscular dystrophy. Anesthesiology 102 5 (2005) 915-919
233. Muenster T., Schmidt J., Wick S., et al. Rocuronium 0.3 mg × kg-1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne's muscular dystrophy. Paediatr Anaesth 16 8 (2006) 840-845
234. Turturro F., Rocca B., Gumina S., et al. Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery. Neuromuscul Disord 15 8 (2005) 532-540
235. Forst J., Forst R., Leithe H., et al. Platelet function deficiency in Duchenne muscular dystrophy. Neuromuscul Disord 8 1 (1998) 46-49